On January 25, 2022, the Food and Drug Administration approved tebentafusp-tebn (Kimmtrak, Immunocore Limited), a bispecific gp100 peptide-HLA-directed CD3 T cell engager, for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
The Association for Clinical Oncology (ASCO) submitted comments in response to the Centers for Medicare & Medicaid Services’ (CMS) Patient Protection and Affordable Care Act 2023 Notice of Benefit and Payment Parameters proposed rule.
On January 13, 2022, the U.S. Supreme Court ruled to allow the Centers for Medicare & Medicaid Services to enforce its vaccine mandate nationwide (with the exception of Texas). At the same time, the Court blocked the U.S. Occupational Safety and Health Administration from enforcing the large-employer vaccine mandate under an Emergency Temporary Standard. Physician offices are not subject to the mandate, but physicians and other providers admitting and/or treating patients in-person within a facility subject to CMS’ health and safety regulations and included in the mandate must be vaccinated so that the facility is compliant.
In many areas of the United States, the healthcare system is facing critical workforce shortages. The American Society of Clinical Oncology (ASCO) encourages public health officials and healthcare facilities to follow Centers for Disease Control and Prevention (CDC) guidelines for managing healthcare personnel with SARS-CoV-2 infection or exposure to SARS-CoV-2. These guidelines allow for different levels of restrictions on staffing based on the level of shortages being experienced. However, in making these decisions, ASCO strongly encourages institutions and public health agencies to recognize the greater risk of infection and adverse outcomes that immune-suppressed individuals, including many patients with cancer, face from SARS-CoV-2 and to make decisions about staffing for the care of those individuals with thoughtful consideration of that greater risk. Unless no alternative exists, COVID-19 positive health workers, even if asymptomatic, should not be assigned to care for patients with cancer
The Centers for Medicare & Medicaid Services (CMS) released the 2023 Medicare Advantage and Part D proposed rule. The proposal aims to advance the administration’s efforts to improve consumer protections, reduce disparities, and improve health equity in Medicare Advantage (MA) and Part D.
The U.S. Department of Health and Human Services (HHS) has announced the availability of nearly $48 million in grants for community-based organizations to expand public health capacity in rural and tribal communities through health care job development, training, and placement.
A large study of EHRs published on January 5, 2022, in JCO Clinical Cancer Informatics uses CancerLinQ data to further highlight the need to minimize the administrative burden of quality reporting and to strengthen the use of data standards to improve the real-world quality of care for patients with cancer.
On December 29, 2021, CMS issued a final rule rescinding the Most Favored Nation (MFN) model. MFN was originally proposed in November 2020 and scheduled to be implemented on January 1, 2021.